Clinical Trials and Research

AbstractBackground and Objectives: Hereditary transthyretin amyloidosis (ATTRv) is a rare disease caused by pathogenic variants in the transthyretin (TTR) gene.…

Isatuximab monotherapy resulted in promising hematologic response rates with a good safety profile among patients with relapsed/refractory (R/R) light chain (AL)…

Light-chain (AL) amyloidosis is a rare systemic disorder characterized by the deposition of misfolded protein aggregates into various organs such as the heart,…

In a letter published in HemaSphere, Claudia Bellofiore, MD, of the University of Pavia in Italy, and colleagues highlighted the need to expand clinical trial…

No FDA approved drugs exist for relapsed/refractory (RR) AL Amyloidosis. CAR-T is a novel approach. We report safety and efficacy from the first 23 pts in NEXICART-…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure that has historically been underdiagnosed due to nonspecific…

Immunoglobulin light chain (AL) amyloidosis is a rare and potentiallylife‐threatening disorder characterized by the deposition ofmisfolded, toxic immunoglobulin…

AbstractIntroduction: Cardiac amyloidosis, primarily comprising transthyretin amyloid cardiomyopathy (ATTR-CM) and light-chain amyloidosis with cardiac involvement…

AbstractBackground and aim of the studyWild-type transthyretin cardiac amyloidosis (ATTRwt-CA) is an increasingly recognized disease in elderly individuals. We…

AbstractIntroductionTransthyretin amyloidosis (ATTR) is a multisystemic disease impacting quality of life (QOL) through various symptoms. The Transthyretin…